DIAGENS 德适生物

Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

VOLUNTARY ANNOUNCEMENT SELECTION AS A CONSTITUENT OF CERTAIN INDEXES OF HANG SENG INDEXES COMPANY LIMITED

This announcement is made by Hangzhou Diagens Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has been selected by the Hang Seng Indexes Company Limited as a constituent stock of 23 Hang Seng Indexes, including (i) the Hang Seng Composite Index, together with Hang Seng Composite LargeCap & MidCap Index, with effect from Monday, September 7, 2026; (ii) the Hang Seng Biotech Index with effect from Monday, September 14, 2026; and (iii) the Hang Seng SCHK Artificial Intelligence Theme Index with effect from Monday, September 14, 2026.

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalisation of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The Hang Seng Biotech Index reflects the overall performance of the 30 largest biotech companies that are listed in Hong Kong, including stocks listed on the Stock Exchange through Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Hang Seng SCHK Artificial Intelligence Theme Index aims to reflect the performance of Hong Kong listed companies enabling the advancement of artificial intelligence, with particular emphasis on key capabilities such as computing power, algorithms, model development, cloud infrastructure and robotics.

Being selected as a constituent stock of the above Hang Seng Indexes fulfills the eligibility criteria for Southbound Trading under the Stock Connect scheme, which is a channel that facilitates stock trading and investment between Hong Kong and a broader base of Chinese Mainland investors.

The Board believes that the Company's inclusion as a constituent of the Hang Seng Composite Index, the Hang Seng Biotech Index and the Hang Seng SCHK Artificial Intelligence Theme Index reflects the capital market's recognition of and confidence in the Company's long-term growth potential. Moreover, this milestone is anticipated to introduce the Company's shares to a broader range of index funds and core portfolios of institutional investors, which will help diversify the investor base, boost trading liquidity, and enhance resilience against risks.

The Board appreciates the continued support from the shareholders and investors of the Company.

About the Group

The Group is a technology company dedicated to revolutionizing medical diagnosis through artificial intelligence. The Group has developed iMedImage®, a foundation model that serves as the "core general-purpose brain" for medical imaging, and has built upon it the iMedLoop™ medical imaging AI research and production acceleration platform. This platform functions like a smart factory, combining medical imaging data with doctors' clinical experience. It not only assists experts in developing new models and research tools more efficiently and expanding the upper limits of medical research and diagnostic innovation; but also transforms expert experience into replicable and deployable models and products, so as to improve the efficiency and quality of medical imaging diagnostics.

Forward-looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board, Executive Director and General Manager

Hangzhou, PRC, August 24, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.